Eli Lilly (NYSE: LLY) has been experiencing significant growth in sales, largely attributed to the success of Zepbound, a weight loss medication that has quickly become a billion-dollar product since its approval in late 2023. However, recent developments suggest that Lilly may have another potential blockbuster in the making.
Zepbound, powered by the active ingredient tirzepatide, is the first dual GLP-1/GIP agonist to receive FDA approval. While it has been a game-changer in the weight loss market, there is a growing demand for an oral alternative to injections. Recognizing this need, Lilly has been working on orforglipron, a once-daily weight management pill that has shown promising results in a phase 3 study. Patients in the trial experienced a significant average weight loss of 7.9% over 40 weeks, along with a 1.5% reduction in A1C levels. The efficacy of orforglipron is on par with injectable GLP-1 medications, making it a potential game-changer in the weight loss industry.
The oral nature of orforglipron makes it easier and more cost-effective to produce and distribute on a global scale, giving Lilly a competitive edge in the market. With the success of Zepbound and the potential of orforglipron, Eli Lilly is poised to solidify its position as a leader in the weight loss pharmaceutical space.
In addition to its advancements in weight loss medications, Eli Lilly has seen success in other areas of its business. Products like Verzenio, a cancer drug, and Taltz, an immunosuppressant, have reported impressive sales growth. The company’s foray into Alzheimer’s disease with Kisunla has also been a significant achievement, defying the odds in a notoriously challenging field.
Beyond its individual products, Eli Lilly’s strength lies in its innovation across multiple therapeutic areas, including diabetes, oncology, and immunology. The company’s track record of clinical and regulatory successes has led to the introduction of several blockbuster drugs, driving revenue and earnings growth.
Moreover, Eli Lilly stands out as a reliable dividend-paying stock, with a history of dividend increases and a conservative payout ratio. While the stock has already seen a boost following the orforglipron news, there is still potential for further upside for investors who are willing to weather market volatility.
Before investing in Eli Lilly, it is important to consider the broader market landscape and explore other investment opportunities. The Motley Fool Stock Advisor team has identified 10 stocks with significant growth potential, offering investors the opportunity to capitalize on emerging trends and potentially achieve substantial returns.
In conclusion, Eli Lilly’s recent successes in the weight loss market, coupled with its innovative pipeline and strong financial performance, position the company as a compelling investment opportunity for those looking to capitalize on the evolving healthcare landscape.
